Cover Image

Detection rate of prostate cancer in repeat biopsy after an initial negative magnetic resonance imaging/ultrasound-guided biopsy

A negative multiparametric magnetic resonance imaging (mpMRI)-guided prostate biopsy in patients with suspected prostate cancer (PC) results in clinical uncertainty, as the biopsy can be false negative. The clinical challenge is to determine the optimal follow-up and to select patients who will bene...

Full description

Saved in:
Bibliographic Details
Main Authors: Görtz, Magdalena (Author) , Huber, Ann-Kathrin (Author) , Linz, Tim (Author) , Schwab, Constantin (Author) , Stenzinger, Albrecht (Author) , Goertz, Lukas (Author) , Bonekamp, David (Author) , Schlemmer, Heinz-Peter (Author) , Hohenfellner, Markus (Author)
Format: Article (Journal)
Language:English
Published: 17 May 2023
In: Diagnostics
Year: 2023, Volume: 13, Issue: 10, Pages: 1-16
ISSN:2075-4418
DOI:10.3390/diagnostics13101761
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.3390/diagnostics13101761
Verlag, kostenfrei, Volltext: https://www.mdpi.com/2075-4418/13/10/1761
Get full text
Author Notes:Magdalena Görtz, Ann-Kathrin Huber, Tim Linz, Constantin Schwab, Albrecht Stenzinger, Lukas Goertz, David Bonekamp, Heinz-Peter Schlemmer and Markus Hohenfellner
Description
Summary:A negative multiparametric magnetic resonance imaging (mpMRI)-guided prostate biopsy in patients with suspected prostate cancer (PC) results in clinical uncertainty, as the biopsy can be false negative. The clinical challenge is to determine the optimal follow-up and to select patients who will benefit from repeat biopsy. In this study, we evaluated the rate of significant PC (sPC, Gleason score ≥7) and PC detection in patients who received a follow-up mpMRI/ultrasound-guided biopsy for persistent PC suspicion after a negative mpMRI/ultrasound-guided biopsy. We identified 58 patients at our institution that underwent repeat targeted biopsy in case of PI-RADS lesions and systematic saturation biopsy between 2014 and 2022. At the initial biopsy, the median age was 59 years, and the median prostate specific antigen level was 6.7 ng/mL. Repeat biopsy after a median of 18 months detected sPC in 3/58 (5%) patients and Gleason score 6 PC in 11/58 (19%). Among 19 patients with a downgraded PI-RADS score at the follow-up mpMRI, none had sPC. In conclusion, men with an initial negative mpMRI/ultrasound-guided biopsy had a high likelihood of not harboring sPC at repeat biopsy (95%). Due to the small size of the study, further research is recommended.
Item Description:Gesehen am 30.11.2023
Physical Description:Online Resource
ISSN:2075-4418
DOI:10.3390/diagnostics13101761

Similar Items